Disease risk management software Dr. Noon Fundus

screeningmedicalophthalmology

Retina-based AI solution that diagnoses retinal abnormalities - Regulation Info - Dr. Noon Fundus_Korea MFDS : [Product Name] DrNoon for fundus screening / [Product License No.] 제허 20-618호 / [Date of Initial Approval] 8 October 2020 / [Validity Period] 8 October 2020 – 30 November 2030 / [Issuer] The Ministry of Food and Drug Safety - Dr. Noon Fundus_CE : EC Certificate issued under the European Medical Device Regulation (EU MDD) / [EC Certificate No.] KR21/81826550 / [First Issue Date] 11 May 2021 / [Expiry Date] 31 December 2028 / [Issuer] SGS Belgium NV - AI-powered Solution for Diagnosing Retinal Abnormalities Dr. Noon Fundus is a retina-based AI diagnostic software that diagnoses retinal abnormalities. By analyzing a single retinal photograph, it automatically detects four types of retinal abnormalities: Glaucoma, Media Opacity, Age-related Macular Degeneration, Diabetic Retinopathy. Dr. Noon Fundus assists ophthalmologists, primary care physicians, and screening centers in making diagnoses related to retinal abnormalities. - Retinal Abnormalities Detectable with Dr. Noon Fundus - Glaucoma (Suspect): Glaucoma is a disease that damages the optic nerve in the eyes. Often known as a silent killer, if left untreated, it will lead to permanent vision loss. *Source - National Eye Institute, National Institutes of Health - Media Opacity: A Media Opacity is a clouding of the lens in the eye that affects vision. Most Media Opacity are related to aging and are commonly found among older people. *Source - National Eye Institute, National Institutes of Health - Age-related Macular Degeneration (AMD): Age-related Macular Degeneration (AMD) is an age-related deterioration of the vision focal point in your eye. AMD can interfere with daily activities such as driving, reading, and writing. *Dr. Noon Fundus screens for age-related macular degeneration and the report flags it as retina normal or abnormal. *Source - National Eye Institute, National Institutes of Health - Diabetic Retinopathy (DR): Diabetic Retinopathy (DR) is a common complication of diabetes leading to severe and permanent blindness. As DR is asymptomatic in the early stages, patients may not notice any change in their vision at first. *Dr. Noon Fundus screens for Diabetic Retinopathy (DR) and the report flags it as retina normal or abnormal. *Source - National Eye Institute, National Institutes of Health - Patient Journey - STEP 1: Eye Scan - Take one picture of each eye to capture the retina. - STEP 2: Image Upload - The retinal images are uploaded to the healthcare institution’s server or cloud platform. - STEP 3: AI Analysis - Artificial intelligence automatically analyzes suspected retinal abnormalities. - STEP 4: Result Review - Retinal abnormalities are determined through a promptly delivered report. - Key Benefits - High Accuracy: Based on learning from more than 100,000 retinal images verified by ophthalmology experts, we provide highly reliable diagnoses. - Fast Test Results: The testing procedure is the same as existing retinal exams, and results are also delivered promptly. - High Accessibility: Can be utilized in clinics, hospitals, and health screening centers, providing more patients with the opportunity to receive cardiovascular assessments. - Our Customers Dr. Noon Fundus is utilized by leading hospitals, clinics, and check-up centers in Korea and worldwide. - Publications & Webinars - Multi-categorical deep learning neural network to classify retinal images: A pilot study employing small database - Deep Learning Is Effective for Classifying Non-referable versus Referable Eye Condition using Fundus Photographs - Efficacy of deep learning-based artificial intelligence models in screening and referring patients with diabetic retinopathy and glaucoma - Technical Specifications / Features - Product Type: AI software medical device - Function: Automatic analysis of fundus images for diagnosis of major eye diseases - Detectable Conditions: Glaucoma (Suspect), Media Opacity, Age-related Macular Degeneration, Diabetic Retinopathy - Regulatory Approvals: Korea MFDS, CE (EU MDD) - First Approval: 2020 (Korea), 2021 (CE) - Validity: Korea (2020–2030), CE (2021–2028) - Intended Users: Ophthalmologists, primary care physicians, screening centers - Data Source: Over 100,000 retinal images